Kinnate Zeroes In On BRAF Subpopulation For Exarafenib Development Strategy

BeiGene And Partners Present RAF Dimer Inhibitor Data

Kinnate presented early monotherapy and combination data for its pan-RAF inhibitor at AACR, but its prioritization of BRAF Class II drew analyst concerns that its focus might be too narrow.

Kinnate presented Phase I data for its pan-RAF inhibitor, exarafenib • Source: Shutterstock

Kinnate Biopharma, Inc. is putting the bulk of its initial energy into certain patients with non-small cell lung cancer (NSCLC) and melanoma in developing the pan-RAF inhibitor exarafenib as a monotherapy, while at least initially putting less of an emphasis on other patient populations, a strategy that drew concern from an analyst that it would narrow the drug’s market opportunity.

The company presented early data from its Phase I study of exarafenib at the American Association for Cancer Research meeting on 17 April, including both monotherapy data as well as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

27 May 2025

• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

Progress In The Effort To Improve Outcomes In SCLC

26 May 2025

• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

Merus Bispecific Impresses In Head And Neck Cancer

23 May 2025

• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

22 May 2025

• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.